We here investigated the RHM as a novel LIG3 targeting natural compound in MM, given its addiction to LIG3, to provide a framework for the clinical development of a safe and effective LIG3 targeting strategy for Alt-NHEJ-dependent malignancies. Here, LIG3 is linked to Miyoshi myopathy.